IPO Ideas

Go to page

Browse IPO Ideas — market data, blogs, legal pages, and more.

Goldline Pharmaceutical Limited IPO logo

Goldline Pharmaceutical Limited IPO

FPSMEBSEListed
Listed at
59.75
+38.95%

Goldline Pharmaceutical Limited IPO is a SME fixed price IPO. Issue size is 12 Cr. Price band is ₹41 to ₹43 per share. Minimum investment is ₹2.58 L. Lot size is 3000 shares. Open from 12 May 2026 to 14 May 2026. Allotment on 15 May 2026. Listing on 19 May 2026 at BSE. Managed by Cumulative Capital Pvt.Ltd. Registrar: Bigshare Services Pvt Ltd. Key details for GMP, subscription, price, allotment, and listing in one place.

Official documents: RHP.

Goldline Pharmaceutical Limited IPO overview

Goldline Pharmaceutical Limited IPO Key figures

Price band, lot, minimum application, and issue window at a glance.

Price band
₹41 to ₹43
Lot size
3000 shares / lot
Min investment
₹2,58,000
Issue open – close
12 May 2026 → 14 May 2026

Goldline Pharmaceutical Limited IPO important dates

Issue Opens
12 May 2026
Issue Closes
14 May 2026
Allotment
15 May 2026
Listing
19 May 2026

Goldline Pharmaceutical Limited IPO lot size

CategoryLotsSharesAmount
Retail (Min)26,0002,58,000
S-HNI (Min)39,0003,87,000
S-HNI (UPI)39,0003,87,000
S-HNI (Max)721,0009,03,000
B-HNI (Min)824,00010,32,000

Quick Profit Calculator for Goldline Pharmaceutical Limited IPO

Pre-filled: Issue Price = ₹43, Lot Size = 3,000 shares

Investment (2 lots): 2,58,000

If listing at GMP (₹59 est.): +₹96,000 (+37.2%)

CategoryLotsInvestmentAt GMPProfit
Retail (Min)22,58,00059+₹96,000
S-HNI (Min)33,87,00059+₹1,44,000
S-HNI (UPI)33,87,00059+₹1,44,000
S-HNI (Max)79,03,00059+₹3,36,000
B-HNI (Min)810,32,00059+₹3,84,000

Estimated profit based on GMP. Actual listing price may vary.

About Goldline Pharmaceutical Limited IPO

From the company / RHP narrative.

Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments: Goldline Pharma: This category includes 42 products to cater to specialties like Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology. Goldline Cardinal: This category offers 54 products tailored for the Specialty division, serving medical fields such as Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians. Goldline Aayushman: This category comprises 18 products designed for the Specialty division, catering to medical fields such as Pediatricians, Child Specialists, Neonatologists, and General Practitioners. Goldline InLife: This category includes 22 products tailored for the Specialty division, serving Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians. Goldline Wellness: This category includes 10 products tailored Supportive care plays a crucial role in cancer therapy. The company do not manufacture products, it partner with third-party manufacturers who produce the medicines based on its market research and product specifications, ensuring quality and compliance with regulations. All products are marketed and sold under the Goldline brand through our network of distributors, who supply to retailers and wholesalers. The company currently works with 15 manufacturers and 7 distributors, and it also support hospitals and healthcare providers with procurement and material supply. The company sells products across the states of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. Competitive Strengths: Experienced Promoters and Management Team with Industry Knowledge and a Track Record Asset-light Business Model and Competitive Products Scalable Business Model Wide and Diverse Range of Product Offerings Strong Supplier and Vendor Relationships Established Distribution Network

Goldline Pharmaceutical Limited IPO Issue Objective

How the issuer plans to use IPO proceeds.

Prepayment or repayment of all or a portion of certain outstanding borrowings availed by Company General Corporate Purposes Total

Goldline Pharmaceutical Limited IPO FAQs

A quick overview of key terms, dates, and how to track this IPO.

What is Goldline Pharmaceutical Limited IPO?
Goldline Pharmaceutical Limited IPO is a public issue where the company offers its shares to investors through the stock exchange, allowing retail, HNI, and institutional participation.
What is the IPO price band of Goldline Pharmaceutical Limited IPO?
The IPO price band of Goldline Pharmaceutical Limited IPO is ₹₹41 to ₹43 per share, as mentioned in the issue details.
What is the minimum investment required for Goldline Pharmaceutical Limited IPO?
The minimum investment in Goldline Pharmaceutical Limited IPO is ₹2,58,000, based on the applicable lot size for retail investors.
What is the lot size of Goldline Pharmaceutical Limited IPO?
The lot size of Goldline Pharmaceutical Limited IPO is 3000 shares per lot, and applications must be made in multiples of this lot size.
What are the opening and closing dates of Goldline Pharmaceutical Limited IPO?
Goldline Pharmaceutical Limited IPO opens on 12 May 2026 and closes on 14 May 2026, as per the announced schedule.
What is Goldline Pharmaceutical Limited IPO subscription status?
Goldline Pharmaceutical Limited IPO subscription status shows the level of demand across retail, HNI, and institutional investor categories during the issue period.
What is Goldline Pharmaceutical Limited IPO GMP today?
Goldline Pharmaceutical Limited IPO GMP (Grey Market Premium) today is around ₹16, reflecting current grey market activity before listing.
Is Goldline Pharmaceutical Limited IPO GMP positive or negative?
Goldline Pharmaceutical Limited IPO GMP is currently subject to change, based on prevailing grey market trends. GMP may change over time.
What does Goldline Pharmaceutical Limited IPO GMP indicate for listing?
A positive Goldline Pharmaceutical Limited IPO GMP may indicate market interest ahead of listing, while actual listing performance depends on subscription response and market conditions.
When is Goldline Pharmaceutical Limited IPO listing date?
The expected listing date of Goldline Pharmaceutical Limited IPO is 19 May 2026, subject to completion of the allotment process.
Where can I check Goldline Pharmaceutical Limited IPO allotment status?
Goldline Pharmaceutical Limited IPO allotment status can be checked online once the allotment process is completed using application or PAN details.
Can Goldline Pharmaceutical Limited IPO subscription and GMP change before listing?
Yes, Goldline Pharmaceutical Limited IPO subscription figures and GMP may change during the issue period and before listing based on market activity.

Goldline Pharmaceutical Limited IPO Ratings & reviews

Community ratings and reviews — not financial advice.

No ratings yet — be the first to share your experience.

Loading ratings…
Follow the latest IPO & unlisted research on iOS and Android.